Summary: In 227 obese adults with type 2 diabetes and fatty liver disease, 12 months of curcumin 1500 mg daily reduced liver fat, liver stiffness, and HbA1c and improved inflammatory and oxidative-stress markers compared with placebo, with mild gastrointestinal discomfort the main side effect.
PICO Summary
| Element | Detail |
|---|---|
| Population | 227 obese adults with type 2 diabetes and metabolic dysfunction-associated steatotic liver disease (MASLD). |
| Intervention | Oral curcumin 1500 mg daily for 12 months. |
| Comparison | Placebo daily over 12 months (double-blind). |
| Outcome | Curcumin reduced liver fat content, liver stiffness, and HbA1c (all p<0.001), lowered IL-1β and TNF-α, raised TAC, GPx, and SOD, and reduced malondialdehyde. No significant liver or kidney abnormalities; mild GI discomfort most common. |
Curcumin for fatty liver in type 2 diabetes
RCT · obese T2DM with MASLD · 12 months
Over 12 months, curcumin 1500 mg daily lowered liver fat, liver stiffness, and HbA1c versus placebo, with improved inflammatory and oxidative-stress markers and only mild GI upset. Endpoints are imaging and laboratory surrogates, not histology.
Expert Commentary
Curcumin trials usually make me sigh, because the field is full of short, small, heterogeneous studies undermined by the compound’s notoriously poor bioavailability. This one earns more respect than most: twelve months, double-blind, 227 patients, imaging-based liver fat and stiffness rather than just enzymes, and a coherent panel of inflammatory and oxidative-stress markers moving in the expected direction. So my verdict is genuinely more positive than my prior, while staying short of enthusiasm. The endpoints are still surrogates, not histological fibrosis regression or hepatic events, and the result may hinge on the specific formulation used, which limits how I generalise it to whatever a patient buys off a shelf. Can I use this with my patients? As a low-risk adjunct, cautiously yes, for an obese diabetic patient with MASLD who is already doing the foundational work, weight loss, diet, exercise, and appropriate diabetes therapy such as a GLP-1 agonist or pioglitazone. I would pick a bioavailability-enhanced product, warn about mild GI upset and anticoagulant interactions, and frame it as a long-game add-on, never a substitute. Larger trials with hard or histological endpoints would move me further.
References
Yaikwawong M, Kamdee K, Chuengsamarn S. Curcumin attenuates liver steatosis via antioxidant and anti-inflammatory pathways in obese patients with type 2 diabetes mellitus: a randomized controlled trial. Int J Mol Sci. 2025;26(19):9286. doi:10.3390/ijms26199286